Probably, although nobody has yet measured by how much. In a scored survey, 550 US adults on injectable semaglutide put their food noise at a median of 6 out of 20. They recalled a median of 13 for the time before they started [1]. A lab comparison of 79 adults found lower scores in people six months into treatment than in people about to begin [2]. The evidence behind the effect is surveys, interviews and one cross-sectional study, which is enough to say it is real and too little to say how large it is. Whether the same drugs help binge eating disorder is a separate question, covered in GLP-1 drugs and binge eating.
What food noise means
The phrase began as a colloquial one, used by patients and clinicians describing less rumination about food on these drugs, and researchers have been working backward to define it. A 2023 review described it as a form of food cue reactivity, the pull that the sight, smell or thought of food exerts. It proposed a model of what makes that pull stronger or weaker [5].
A measuring instrument came next. The five-item Food Noise Questionnaire was tested in 396 adults and showed a Cronbach’s alpha of 0.93 and a test-retest correlation of 0.79 across about a week [3]. Its developers conclude that it measures food noise reliably and that its clinical usefulness still needs to be evaluated. Every scored result on this page uses that questionnaire.
The INFORM survey
The INFORM survey recruited 550 people from a commercial opinion panel who were taking injectable semaglutide for weight management [1]. Respondents were 86% women and 79% white, with a mean age of 53, and 81% had been on the drug for at least four months.
Scores fell from a recalled median of 13 to a current median of 6, a median change of -5. Agreement with statements indicating food noise dropped from a range of 47% to 63% before the drug to 15% to 20% on it, and the pattern held across subgroups by treatment duration and BMI.
A comparison with people not yet on the drug
A US study recruited 79 adults with obesity in three groups [2]. There were 27 who were eligible but had not started, 25 a month into a GLP-1, and 27 at six months. Food Noise Questionnaire scores were lower in the six-month group than in the pre-use group, P = .026.
Six-month users also scored lower on cue responsiveness, craving and food reward, and ate less. This is the nearest the literature comes to a measured baseline, and it still falls short of one, because each group is made of different people and nobody was followed from the first dose.
What users say when nobody asks about it
The most persuasive evidence is qualitative. Among 1,659 people managed in a virtual setting, participants reported that the drugs reduced food-related thoughts and improved satiety [4]. Reduced food noise also surfaces as a theme in interview research on patient experience, described in what taking a GLP-1 is like.
That consistency is why the effect is taken seriously. It is also why the numbers attached to it deserve care, because a widely shared experience is exactly what a recalled baseline exaggerates. Why people start these drugs, including this reason, is set out in why people start taking a GLP-1.
What a buyer can take from it
Quieter food thoughts are a commonly reported experience on these drugs, and they are not what any of them is approved or priced for. No seller can promise a size of effect, since none has been measured in the same people over time.
None of the studies here followed food noise after the drug stopped, so whether the quiet outlasts treatment is unknown. That matters because most people do not stay on treatment long, as how long people stay on a GLP-1 shows.